MedCity News October 3, 2024
Frank Vinluan

Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026.

It’s getting more expensive to build labs and construction has fallen compared to peak activity during the pandemic. But there’s still plenty of lab space to go around, leaving building owners scrambling to try to fill it, according to findings in a new report this week from commercial real estate and investment firm CBRE.

The pandemic led to a boom in lab construction activity, feeding off of the surge of investments made in life science startups. Much but not all...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Survey / Study, Trends
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article